# US 6,730,673 B1 · Pharmaceutical solutions of levosimendan

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,673 B1
- Document ID: US6730673B1
- Status: Granted
- Kind: B1
- Application number: 10/070,689
- Filed: 2002-07-26
- Granted: 2004-05-04
- Earliest claimed: 1999-09-10
- Assignees: Orion Corporation
- Inventors: Reijo Bäckström; Päivi Granvik; Ritva Haikala; Sirpa Pelttari; Eva Saukko; Reija Yrjölä
- Web page: https://patentgrep.com/patent/US6730673B1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/50: Pyridazines; Hydrogenated pyridazines
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Levosimendan solutions for pharmaceutical use, and particularly for intravenous administration. The solutions of the invention have enhanced stability and they are particularly useful as infusion or injection solutions or infusion concentrates. Levosimendan is useful in the treatment of congestive heart failure.

## Claims

### Claim 1

An aqueous intravenous infusion solution comprising levosimendan or a salt thereof as an active ingredient, the pH-value of the solution being lower than 5, and a solubility enhancing agent, wherein the solubility enhancing agent is polyvinylpyrrolidone or ethanol.

### Claim 2

A pharmaceutical solution, comprising
(a) levosimendan or a pharmaceutically acceptable salt thereof as an active ingredient,
(b) a pharmaceutically acceptable organic solvent comprising ethanol,
(c) a stability enhancing amount of a pharmaceutically acceptable organic acid having pKa in the range of from 2 to 4, and optionally
(d) a water-solubility enhancing agent.

### Claim 3 (depends on 2)

A solution according to claim 2, wherein the amount of said solvent is 90-99.9% by weight of the solution.

### Claim 4 (depends on 2)

A solution according to claim 2, wherein the amount of said organic acid 0.005-2% by weight of the solution.

### Claim 5 (depends on 2)

A solution according to claim 2, wherein the pharmaceutically acceptable organic acid is citric acid is a 2-hydroxy alkanoic acid.

### Claim 6 (depends on 5)

A solution according to claim 5, wherein the pharmaceutically acceptable organic acid is citric acid, lactic acid, tartaric acid or malic acid.

### Claim 7 (depends on 2)

A solution according to claim 2, wherein the amount of the water-solubility enhancing agent is 0.1-5% by weight.

### Claim 8 (depends on 2)

A solution according to claim 2, wherein the water-solubility enhancing agent is polyvinylpyrrolidone.

### Claim 9 (depends on 2)

A solution according to claim 2, comprising
(a) levosimendan or a pharmaceutically acceptable salt thereof in an amount of 0.01-1.0% by weight,
(b) dehydrated ethanol in an amount of 95-99.5% by weight,
(c) citric acid in an amount of 0.03-0.6% by weight, and
(d) polyvinylpyrrolidone in an amount of 0.5-2% by weight.

### Claim 10 (depends on 2)

A solution according to claim 2, wherein the solution is an intravenous infusion concentrate.

### Claim 11 (depends on 2)

A solution according to claim 2, wherein the amount of said solvent is 95-99.9% by weight of the solution.

### Claim 12 (depends on 2)

A solution according to claim 2, wherein the amount of said organic acid is 0.01-1% by weight of the solution.

### Claim 13 (depends on 3)

A solution according to claim 3, wherein the amount of said organic acid is 0.005-2% by weight of the solution.

### Claim 14 (depends on 3)

A solution according to claim 3, wherein the amount of said organic acid is 0.01-1% by weight of the solution.
